ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Lancet Rheumatol · 2026-03-19

In 308 patients with gout and hyperuricaemia in the Netherlands, a treat-to-target urate strategy achieved more remission at months 18-24 than symptom-driven management (39.4% vs 24.0%; difference 15.4 points, p=0.024), with no excess adverse events.

RCTn = 308
Moses et al. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.